Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 12, 2019

AstraZeneca and Seres Therapeutics to study new cancer therapy process

AstraZeneca has formed a research alliance with US-based Seres Therapeutics to explore the use of microbiome in boosting the efficacy of cancer immunotherapy.

AstraZeneca has formed a research alliance with US-based Seres Therapeutics to explore the use of microbiome in boosting the efficacy of cancer immunotherapy.

Seres Therapeutics is engaged in the development of new biological drugs that could restore the function of a dysbiotic microbiome to treat diseases driven by imbalanced bacterial diversity and function.

Under the three-year exclusive partnership, the companies will work to assess microbiome-based approaches as a predictor for which cancer patients may have the best response to some immunotherapies.

According to preclinical and early clinical evidence, clinical response to checkpoint inhibitor immunotherapy is affected by the composition of the gastrointestinal microbiome.

This supports the assumption that alteration of the microbiome may improve outcomes, noted Seres.

“Despite progress in the field of immunotherapy, we are only at the tip of the iceberg. Too many patients are still unable to benefit from existing therapies, so we must continue following the science in pursuit of new and innovative solutions.”

AstraZeneca Research & Development Oncology senior vice-president Jean-Charles Soria said: “Our new collaboration with Seres Therapeutics represents an important opportunity to advance our understanding of the relationship between the microbiome and the immune system’s ability to respond to cancer therapy.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

“Despite progress in the field of immunotherapy, we are only at the tip of the iceberg. Too many patients are still unable to benefit from existing therapies, so we must continue following the science in pursuit of new and innovative solutions.”

The alliance will combine Seres’ expertise in microbiome drug discovery and manufacturing with AstraZeneca’s oncology experience to study the potential of microbiome therapy in combination with other pharmaceutical approaches to improve clinical response.

Moreover, the partners plan to study Seres’ investigational microbiome therapeutic SER-401 in combination with AstraZeneca’s oncology candidates.

Seres Therapeutics president and CEO Eric Shaff said: “Through the activities under this collaboration and in our SER-401 Phase 1b clinical study in metastatic melanoma, we hope to meaningfully advance our understanding of the potential for microbiome therapeutics to magnify the impact of cancer immunotherapy.”

As per the terms of the deal, AstraZeneca will pay $20m in three equal instalments over two years to Seres. The first instalment is due at the start of the agreement.

The pharmaceutical giant has also agreed to reimburse Seres for research activity carried out as part the collaboration.

Seres will retain rights to oncology targeted microbiome therapeutic candidates, and AstraZeneca will hold an option to negotiate for these rights as well as other products resulting from the alliance.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU